NCT00500240View on ClinicalTrials.gov

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

PHASE3TerminatedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
LeukemiaLymphoma
Interventions
DRUG

Insulin Glargine

Use of human insulin glargine for slow decrease of blood sugar level over 24 hours.

DRUG

Insulin Aspart

Use of human insulin aspart for rapid lowering of the blood glucose level over 24 hours.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER